메뉴 건너뛰기




Volumn 62, Issue 8, 2016, Pages 972-979

Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors

Author keywords

direct acting antiviral HCV drugs; hepatitis C; HIV; HIV protease inhibitors; pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DASABUVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; OMBITASVIR; PARITAPREVIR; PARITAPREVIR PLUS RITONAVIR; RITONAVIR; UNCLASSIFIED DRUG; ABT-267; ABT-333; ABT-450; ANILIDE; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; SULFONAMIDE; URACIL;

EID: 84964825681     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ1213     Document Type: Article
Times cited : (33)

References (30)
  • 2
    • 84904568743 scopus 로고    scopus 로고
    • Antiretroviral treatment of adult HIV infection: 2014 recommendations of the international antiviral society-USA panel
    • Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014; 312:410-25.
    • (2014) JAMA , vol.312 , pp. 410-425
    • Gunthard, H.F.1    Aberg, J.A.2    Eron, J.J.3
  • 5
    • 84255173321 scopus 로고    scopus 로고
    • Antiretroviral drug interactions: Overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management
    • Rathbun RC, Liedtke MD. Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management. Pharmaceutics 2011; 3:745-81.
    • (2011) Pharmaceutics , vol.3 , pp. 745-781
    • Rathbun, R.C.1    Liedtke, M.D.2
  • 6
    • 84904647749 scopus 로고    scopus 로고
    • ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection
    • e1
    • Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147:359-65.e1.
    • (2014) Gastroenterology , vol.147 , pp. 359-365
    • Andreone, P.1    Colombo, M.G.2    Enejosa, J.V.3
  • 7
    • 84901044326 scopus 로고    scopus 로고
    • ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV
    • Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370:1983-92.
    • (2014) N Engl J Med , vol.370 , pp. 1983-1992
    • Ferenci, P.1    Bernstein, D.2    Lalezari, J.3
  • 8
    • 84901036125 scopus 로고    scopus 로고
    • ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
    • Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370:1973-82.
    • (2014) N Engl J Med , vol.370 , pp. 1973-1982
    • Poordad, F.1    Hezode, C.2    Trinh, R.3
  • 9
    • 84899068302 scopus 로고    scopus 로고
    • Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
    • Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370:1594-603.
    • (2014) N Engl J Med , vol.370 , pp. 1594-1603
    • Feld, J.J.1    Kowdley, K.V.2    Coakley, E.3
  • 10
    • 84925428093 scopus 로고    scopus 로고
    • Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: A randomized trial
    • Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313:1223-31.
    • (2015) JAMA , vol.313 , pp. 1223-1231
    • Sulkowski, M.S.1    Eron, J.J.2    Wyles, D.3
  • 11
    • 84928334037 scopus 로고    scopus 로고
    • Drug-drug interactions of the direct acting antiviral regimen of ABT-450/r, ombitasvir and dasabuvir with HIV protease inhibitors
    • 5-9 September; Washington, DC
    • Khatri A, Wang H, Wang T, et al. Drug-drug interactions of the direct acting antiviral regimen of ABT-450/r, ombitasvir and dasabuvir with HIV protease inhibitors. Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 5-9 September 2014; Washington, DC.
    • (2014) Presented at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • Khatri, A.1    Wang, H.2    Wang, T.3
  • 12
    • 84964830595 scopus 로고    scopus 로고
    • Rockville, MD: Food and Drug Administration, Accessed 27 January 2016
    • Center for Drug Evaluation and Research (CDER). Application number: 206619Orig1s000 summary review for regulatory action. Rockville, MD: Food and Drug Administration, 2014. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2014/206619Orig1s000SumR.pdf. Accessed 27 January 2016.
    • (2014) Application Number: 206619Orig1s000 Summary Review for Regulatory Action
  • 13
    • 84928569640 scopus 로고    scopus 로고
    • Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir
    • Menon RM, Badri PS, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol 2015; 63:20-9.
    • (2015) J Hepatol , vol.63 , pp. 20-29
    • Menon, R.M.1    Badri, P.S.2    Wang, T.3
  • 14
    • 75149116931 scopus 로고    scopus 로고
    • Treatment-naïve, HCV genotype 1-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone
    • Rodriguez-Torres M, Lawitz E, Cohen D, et al. Treatment-naïve, HCV genotype 1-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone. Hepatology 2009; 50:91A.
    • (2009) Hepatology , vol.50 , pp. 91
    • Rodriguez-Torres, M.1    Lawitz, E.2    Cohen, D.3
  • 16
    • 84866784148 scopus 로고    scopus 로고
    • ABT-267 combined with pegylated interferon alpha-2a/ribavirin in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12 week antiviral and safety analysis
    • Sullivan GJ, Rodrigues-Torres M, Lawitz E, et al. ABT-267 combined with pegylated interferon alpha-2a/ribavirin in genotype 1 (GT1) HCV-infected treatment-naive subjects: 12 week antiviral and safety analysis. J Hepatology 2012; 56: S480.
    • (2012) J Hepatology , vol.56 , pp. S480
    • Sullivan, G.J.1    Rodrigues-Torres, M.2    Lawitz, E.3
  • 17
    • 84871765489 scopus 로고    scopus 로고
    • Exploratory study of oral combination antiviral therapy for hepatitis C
    • Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368:45-53.
    • (2013) N Engl J Med , vol.368 , pp. 45-53
    • Poordad, F.1    Lawitz, E.2    Kowdley, K.V.3
  • 18
    • 84964916095 scopus 로고    scopus 로고
    • Study of ABT-267 2-day monotherapy followed by 12-week combination therapy in treatment-naive patients with chronic HCV genotype 1 infection
    • Epstein M, Felizarta F, Marbury T, et al. Study of ABT-267 2-day monotherapy followed by 12-week combination therapy in treatment-naive patients with chronic HCV genotype 1 infection. J Hepatol 2013; 58:S484.
    • (2013) J Hepatol , vol.58 , pp. S484
    • Epstein, M.1    Felizarta, F.2    Marbury, T.3
  • 19
    • 84892591928 scopus 로고    scopus 로고
    • Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1
    • Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370:222-32.
    • (2014) N Engl J Med , vol.370 , pp. 222-232
    • Kowdley, K.V.1    Lawitz, E.2    Poordad, F.3
  • 20
    • 84964901252 scopus 로고    scopus 로고
    • Pharmacokinetic/pharmacodynamic (PK/PD) analyses of darunavir in the TITAN study
    • 24-27 October 2014; Madrid, Spain
    • Sekar V, De Paepe E, Van Baelen B, et al. Pharmacokinetic/pharmacodynamic (PK/PD) analyses of darunavir in the TITAN study. Presented at: 11th Annual European AIDS Conference; 24-27 October 2014, 2007; Madrid, Spain.
    • (2007) Presented at: 11th Annual European AIDS Conference
    • Sekar, V.1    De Paepe, E.2    Van Baelen, B.3
  • 22
    • 84878550510 scopus 로고    scopus 로고
    • Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twicedaily darunavir/ritonavir (DRV/r) in the ODIN trial [abstract]
    • Sekar V, De La Rosa G, Van de Casteele T, Spinosa-Guzman S, Vis P, Hoetelmans RMW. Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twicedaily darunavir/ritonavir (DRV/r) in the ODIN trial [abstract]. J Int AIDS Soc 2010; 13:P185.
    • (2010) J Int AIDS Soc , vol.13 , pp. 185
    • Sekar, V.1    De La-Rosa, G.2    Van De-Casteele, T.3    Spinosa-Guzman, S.4    Vis, P.5    Hoetelmans, R.M.W.6
  • 23
  • 25
    • 84957885452 scopus 로고    scopus 로고
    • Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir/ritonavir (2D regimen)
    • Badri PS, Dutta S, Wang H, et al. Drug interactions with the direct-acting antiviral combination of ombitasvir and paritaprevir/ritonavir (2D regimen). Antimicrob Agents Chemother 2015; 60:105-14.
    • (2015) Antimicrob Agents Chemother , vol.60 , pp. 105-114
    • Badri, P.S.1    Dutta, S.2    Wang, H.3
  • 26
    • 84964864052 scopus 로고    scopus 로고
    • Dose- and formulation dependent nonlinear pharmacokinetic model of ABT-450, a protease inhibitor for the treatment of HCV: Combined analyses from 12 phase 1 studies
    • Polepally A, Mensing S, Khatri A, et al. Dose- and formulation dependent nonlinear pharmacokinetic model of ABT-450, a protease inhibitor for the treatment of HCV: combined analyses from 12 phase 1 studies. J Pharmacokinet Pharmacodyn 2014; 41(suppl):S7-101.
    • (2014) J Pharmacokinet Pharmacodyn , vol.41 , pp. S7-S101
    • Polepally, A.1    Mensing, S.2    Khatri, A.3
  • 27
    • 84952984602 scopus 로고    scopus 로고
    • Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir, and ribavirin in patients with hepatitis C virus genotype 1 infection: Combined analysis from 9 phase 1b/2 studies
    • Mensing S, Polepally A, Koenig D, et al. Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir, and ribavirin in patients with hepatitis C virus genotype 1 infection: combined analysis from 9 phase 1b/2 studies. AAPS J 2016; 18:270-80.
    • (2016) AAPS J , vol.18 , pp. 270-280
    • Mensing, S.1    Polepally, A.2    Koenig, D.3
  • 28
    • 70249084706 scopus 로고    scopus 로고
    • Rockville, MD: Food and Drug Administration
    • U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. Rockville, MD: Food and Drug Administration, 2009.
    • (2009) Guidance for Industry. Drug-induced Liver Injury: Premarketing Clinical Evaluation
  • 30
    • 84964857062 scopus 로고    scopus 로고
    • TURQUOISE-I study: Use of ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in patients with HCV/HIV-1 coinfection on stable darunavir-containing antiretroviral therapy
    • 21-24 October; Barcelona, Spain
    • Ruane P, Adeyemi O, Trinh R, et al. TURQUOISE-I study: use of ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in patients with HCV/HIV-1 coinfection on stable darunavir-containing antiretroviral therapy. Presented at: 15th European AIDS Conference; 21-24 October 2015; Barcelona, Spain.
    • (2015) Presented at: 15th European AIDS Conference
    • Ruane, P.1    Adeyemi, O.2    Trinh, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.